Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-Label, Single-Arm, Phase 2, Multicenter Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-Cell Prolymphocytic Leukemia

NCT03873493 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03873493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03873493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-Label, Single-Arm, Phase 2, Multicenter Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-Cell Prolymphocytic Leukemia
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
January 14, 2020
Completion date
November 4, 2021
Enrollment
14 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, leukemia, t-cell prolymphocytic leukemia (t-pll)